查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2130755

智慧胰島素輸注系統市場分析與預測（至2035年）：類型、產品類型、技術、組件、應用、設備、最終用戶、功能、解決方案、給藥模式

Smart Insulin Delivery Systems Market Analysis and Forecast to 2035: Type, Product, Technology, Component, Application, Device, End User, Functionality, Solutions, Mode
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球智慧胰島素輸注系統市場預計將從2025年的99億美元成長到2035年的194億美元，複合年成長率（CAGR）為7.0%。智慧胰島素輸注系統市場成長的驅動力在於對自動化血糖管理、個人化胰島素輸注和互聯糖尿病護理技術的需求。 2026年6月，美國食品藥物管理局（FDA）批准了Omnipod 6自動胰島素輸注系統，該系統整合了自動胰島素輸注演算法、ACE胰島素幫浦和相容的持續血糖監測儀（CGM）。智慧型系統日益整合了CGM、胰島素幫浦、輸注演算法、智慧型手機連接和預測性血糖控制等功能，進而實現胰島素劑量的自動調節。這些技術支援更個人化的糖尿病管理，同時減少了手動注射的需求，並實現了持續、協調的監測。

智慧胰島素輸注系統市場的「類型」細分包括持續血糖監測系統、智慧胰島素筆、胰島素幫浦、閉合迴路系統及其他產品。預計到2025年，胰島素幫浦將佔據市場主導地位，因為它們能夠實現精準、持續的胰島素輸注，並支持個人化的糖尿病管理。閉合迴路系統預計將成為成長最快的細分市場。人工智慧、機器學習、互聯技術和感測器技術的進步可望進一步提升閉合迴路系統的性能和應用。

市場區隔
種類 持續血糖監測系統、智慧胰島素筆、胰島素幫浦、閉合迴路系統等。
產品 穿戴式裝置、植入式裝置、手持裝置、配件及其他
科技 藍牙、Wi-Fi、近距離場通訊（NFC）、人工智慧、機器學習、物聯網（IoT）、雲端運算及其他
成分 感測器、發送器、接收器、軟體及其他
目的 1型糖尿病、第2型糖尿病、妊娠糖尿病及其他
裝置 貼片式胰島素幫浦、有線胰島素幫浦、智慧胰島素筆等。
最終用戶 醫院、居家照護、專科診所、糖尿病護理中心及其他
功能 即時監測、數據分析、自動胰島素注射、遠端監測等等。
解決方案 整合系統、獨立系統及其他
方法 侵入性、非侵入性及其他。

智慧胰島素輸注系統市場的終端使用者包括醫院、居家照護機構、專科診所、糖尿病照護中心等。預計到2025年，居家照護機構將成為市場成長的主導，這主要得益於人們對在臨床環境之外進行便利、持續和技術驅動的糖尿病管理的需求不斷成長。聯網的胰島素輸注設備使患者和看護者能夠遠端監測治療狀態並管理胰島素輸注。在預測期內，糖尿病照護中心預計將成為成長最快的細分市場，這主要得益於糖尿病盛行率的上升、專業疾病管理計畫的開展以及整合血糖監測和胰島素輸注技術的日益普及。由於人們越來越關注個人化糖尿病護理和遠端患者監護，預計專業糖尿病護理機構也將進一步採用這些技術。

區域概覽

預計到2025年，北美將成為智慧胰島素輸注系統市場的主導地區。這得益於該地區先進的糖尿病護理基礎設施、互聯胰島素輸注技術的高普及率、強勁的醫療費用支出以及完善的保險報銷體系。智慧胰島素筆、胰島素幫浦、持續血糖監測和自動化胰島素輸注系統的廣泛應用，使該地區受益匪淺。美國是主要貢獻者，這得益於其龐大的胰島素治療需求人群、先進的內分泌和糖尿病護理網路以及強大的醫療設備製造商網路。胰島素輸注系統與數位健康平台、遠端監測和個人化治療技術的日益融合，進一步推動了該地區的需求成長。

在預測期內，亞太地區預計將成為智慧胰島素輸注系統市場成長最快的地區，其主要驅動力包括糖尿病盛行率上升、醫療基礎設施不斷完善、醫療支出持續成長以及互聯自動化胰島素輸注技術的日益普及。隨著先進糖尿病管理解決方案的可近性不斷提高，中國、印度、日本、韓國和澳洲預計將為該地區的市場擴張做出顯著貢獻。政府措施的增加、保險覆蓋範圍的擴大、數位醫療的普及以及對智慧胰島素筆、胰島素幫浦和自動化輸注系統的投資，預計將進一步推動市場發展。此外，市場對便利性、個人化和微創糖尿病管理解決方案的需求不斷成長，也將進一步加速全部區域智慧胰島素輸注系統的應用。

主要趨勢和促進因素

過渡到全自動、自適應胰島素輸注：

智慧胰島素輸注系統市場正朝著高度自動化系統轉型，這些系統整合了持續血糖監測（CGM）、胰島素幫浦、預測演算法和自適應控制軟體，能夠即時調節胰島素輸注。新一代系統正在超越傳統的混合封閉回路型運作模式，減少手動記錄餐點和其他使用者介入的需求。人工智慧和機器學習技術正被研究用於根據個體血糖模式、胰島素敏感性、飲食、運動和晝夜節律變化來個性化胰島素劑量。美國糖尿病協會（ADA）發布的《2026年治療指南》明確指出，自動胰島素輸注（AID）是1型糖尿病患者的建議治療方法，這將進一步加速向智慧化和自動化治療的過渡。

改善血糖控制和減少低血糖發生的需求日益成長：

智慧胰島素輸注系統的主要市場促進因素之一是需要在無需頻繁手動調整胰島素劑量的情況下，降低高血糖和低血糖的發生率，同時延長血糖在血糖水平下的維持時間。智慧輸注系統持續利用動態血糖監測（CGM）數據和控​​制演算法，根據血糖值的變化自動增加、減少或暫停胰島素劑量。根據2026年美國糖尿病協會（ADA）治療標準報告，與傳統胰島素輸注方法相比，智慧胰島素輸注系統（AID）已被證實能夠延長血糖在血糖水平下的維持時間，降低糖化血紅蛋白（HbA1c）水平，並減少低血糖的發生。此外，該證據不僅適用於第1型糖尿病患者；2026年的一項系統綜述顯示，AID系統也能改善接受胰島素治療的第二型糖尿病患者的血糖控制，並減少低血糖的發生。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 連續血糖監測系統
    • 智慧胰島素筆
    • 胰島素幫浦
    • 封閉回路型系統
    • 其他
  • 市場規模及預測：依產品分類
    • 穿戴式裝置
    • 植入式醫療設備
    • 手持裝置
    • 配件
    • 其他
  • 市場規模及預測：依技術分類
    • Bluetooth
    • Wi-Fi
    • 近距離場通訊（NFC）
    • 人工智慧
    • 機器學習
    • 物聯網 (IoT)
    • 雲端運算
    • 其他
  • 市場規模及預測：依組件分類
    • 感應器
    • 發送器
    • 接收器
    • 軟體
    • 其他
  • 市場規模及預測：依應用領域分類
    • 1型糖尿病
    • 2型糖尿病
    • 妊娠糖尿病
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 居家醫療
    • 專科診所
    • 糖尿病護理中心
    • 其他
  • 市場規模及預測：功能
    • 即時監控
    • 資料分析
    • 自動胰島素注射
    • 遠端監控
    • 其他
  • 市場規模及預測：依設備分類
    • 貼片幫浦
    • 有線泵
    • 智慧胰島素筆
    • 其他
  • 市場規模及預測：按解決方案分類
    • 整合系統
    • 獨立系統
    • 其他
  • 市場規模及預測：按模式
    • 侵入性
    • 非侵入性
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 大公司的策略

第8章：公司簡介

  • Medtronic
  • Insulet Corporation
  • Tandem Diabetes Care
  • Dexcom
  • Abbott Laboratories
  • Roche Diabetes Care
  • Ypsomed
  • Novo Nordisk
  • Sanofi
  • Eli Lilly and Company
  • Beta Bionics
  • Bigfoot Biomedical
  • Glooko
  • Diabeloop
  • Senseonics
  • Biocon
  • Cellnovo
  • Valeritas
  • DreaMed Diabetes
  • SmartDose Technologies,

第9章 關於我們

簡介目錄
Product Code: GIS10750

The global Smart Insulin Delivery Systems Market is projected to grow from $9.9 billion in 2025 to $19.4 billion by 2035, at a compound annual growth rate (CAGR) of 7.0%. The Smart Insulin Delivery Systems Market is driven by demand for automated glucose management, personalized insulin dosing, and connected diabetes-care technologies. In June 2026, the U.S. FDA cleared the Omnipod 6 Automated Insulin Delivery System, combining an automated insulin-dosing algorithm, ACE pump, and compatible continuous glucose monitor. Smart systems increasingly integrate CGMs, insulin pumps, dosing algorithms, smartphone connectivity, and predictive glucose control to automatically adjust insulin delivery. These technologies are supporting more personalized diabetes management while reducing manual dosing requirements and enabling continuous, connected monitoring.

The Type segment of the Smart Insulin Delivery Systems Market includes Continuous Glucose Monitoring Systems, Smart Insulin Pens, Insulin Pumps, Closed-loop Systems, and Others. Insulin Pumps dominated the market in 2025 due to their ability to provide precise, continuous insulin delivery and support personalized diabetes management. Increasing integration with continuous glucose monitoring and automated dosing technologies is further supporting adoption. Closed-loop Systems are expected to be the fastest-growing segment during the forecast period, driven by increasing demand for automated insulin delivery, real-time glucose monitoring, and improved glycemic management. Advancements in artificial intelligence, machine learning, connectivity, and sensor technologies are expected to further enhance the performance and adoption of closed-loop systems.

Market Segmentation
TypeContinuous Glucose Monitoring Systems, Smart Insulin Pens, Insulin Pumps, Closed-loop Systems, Others
ProductWearable Devices, Implantable Devices, Handheld Devices, Accessories, Others
TechnologyBluetooth, Wi-Fi, Near Field Communication (NFC), Artificial Intelligence, Machine Learning, Internet of Things (IoT), Cloud Computing, Others
ComponentSensors, Transmitters, Receivers, Software, Others
ApplicationType 1 Diabetes, Type 2 Diabetes, Gestational Diabetes, Others
DevicePatch Pumps, Tethered Pumps, Smart Insulin Pens, Others
End UserHospitals, Home Care Settings, Specialty Clinics, Diabetes Care Centers, Others
FunctionalityReal-time Monitoring, Data Analytics, Automated Insulin Delivery, Remote Monitoring, Others
SolutionsIntegrated Systems, Standalone Systems, Others
ModeInvasive, Non-invasive, Others

The End User segment of the Smart Insulin Delivery Systems Market includes Hospitals, Home Care Settings, Specialty Clinics, Diabetes Care Centers, and Others. Home Care Settings dominated the market in 2025 due to the growing preference for convenient, continuous, and technology-enabled diabetes management outside clinical environments. Connected insulin delivery devices enable patients and caregivers to monitor treatment and manage insulin administration remotely. Diabetes Care Centers are expected to be the fastest-growing segment during the forecast period, supported by increasing diabetes prevalence, specialized disease-management programs, and greater adoption of integrated glucose monitoring and insulin delivery technologies. Growing emphasis on personalized diabetes care and remote patient monitoring is expected to further increase adoption in specialized diabetes care settings.

Geographical Overview

North America was the leading region in the Smart Insulin Delivery Systems Market in 2025, supported by advanced diabetes-care infrastructure, high adoption of connected insulin delivery technologies, strong healthcare expenditure, and established reimbursement systems. The region benefits from widespread use of smart insulin pens, insulin pumps, continuous glucose monitoring, and automated insulin delivery systems. The United States represents the major contributor, supported by a large population requiring insulin therapy, sophisticated endocrinology and diabetes-care networks, and strong presence of medical-device manufacturers. Increasing integration of insulin delivery systems with digital health platforms, remote monitoring, and personalized treatment technologies further supported regional demand.

Asia-Pacific is expected to be the fastest-growing region in the Smart Insulin Delivery Systems Market during the forecast period, driven by the rising prevalence of diabetes, expanding healthcare infrastructure, increasing healthcare expenditure, and growing adoption of connected and automated insulin delivery technologies. China, India, Japan, South Korea, and Australia are expected to contribute significantly to regional expansion as access to advanced diabetes-management solutions improves. Growing government initiatives, expanding insurance coverage, increasing digital-health adoption, and investments in smart insulin pens, pumps, and automated delivery systems are expected to support market development. The growing demand for convenient, personalized, and minimally invasive diabetes-management solutions will further encourage adoption across the region.

Key Trends and Drivers

Shift Toward Fully Automated, Adaptive Insulin Delivery:

The Smart Insulin Delivery Systems Market is trending toward increasingly autonomous systems that integrate continuous glucose monitoring (CGM), insulin pumps, predictive algorithms, and adaptive control software to adjust insulin delivery in real time. Next-generation systems are moving beyond conventional hybrid closed-loop operation toward reducing the need for manual meal announcements and other user interventions. AI and machine-learning approaches are being investigated to personalize insulin dosing according to individual glucose patterns, insulin sensitivity, meals, exercise, and daily variability. The American Diabetes Associations 2026 Standards of Care identify automated insulin delivery (AID) as the preferred insulin-delivery method for people with type 1 diabetes, reinforcing the shift toward intelligent, automated therapy.

Growing Demand for Better Glycemic Control and Reduced Hypoglycemia:

A major driver for the Smart Insulin Delivery Systems Market is the need to improve time in glucose range while reducing hyperglycemia and hypoglycemia without requiring constant manual insulin adjustments. Smart delivery systems continuously use CGM data and control algorithms to increase, decrease, or suspend insulin delivery according to changing glucose levels. The 2026 ADA Standards report that AID systems improve time in range, lower A1C, and reduce hypoglycemia compared with conventional insulin-delivery approaches. Evidence is also expanding beyond type 1 diabetes, with a 2026 systematic review finding that AID improved glucose control and reduced hypoglycemia in insulin-treated people with type 2 diabetes.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Component
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Functionality
  • 2.8 Key Market Highlights by Device
  • 2.9 Key Market Highlights by Solutions
  • 2.10 Key Market Highlights by Mode

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Continuous Glucose Monitoring Systems
    • 4.1.2 Smart Insulin Pens
    • 4.1.3 Insulin Pumps
    • 4.1.4 Closed-loop Systems
    • 4.1.5 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Wearable Devices
    • 4.2.2 Implantable Devices
    • 4.2.3 Handheld Devices
    • 4.2.4 Accessories
    • 4.2.5 Others
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Bluetooth
    • 4.3.2 Wi-Fi
    • 4.3.3 Near Field Communication (NFC)
    • 4.3.4 Artificial Intelligence
    • 4.3.5 Machine Learning
    • 4.3.6 Internet of Things (IoT)
    • 4.3.7 Cloud Computing
    • 4.3.8 Others
  • 4.4 Market Size & Forecast by Component (2020-2035)
    • 4.4.1 Sensors
    • 4.4.2 Transmitters
    • 4.4.3 Receivers
    • 4.4.4 Software
    • 4.4.5 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Type 1 Diabetes
    • 4.5.2 Type 2 Diabetes
    • 4.5.3 Gestational Diabetes
    • 4.5.4 Others
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Home Care Settings
    • 4.6.3 Specialty Clinics
    • 4.6.4 Diabetes Care Centers
    • 4.6.5 Others
  • 4.7 Market Size & Forecast by Functionality (2020-2035)
    • 4.7.1 Real-time Monitoring
    • 4.7.2 Data Analytics
    • 4.7.3 Automated Insulin Delivery
    • 4.7.4 Remote Monitoring
    • 4.7.5 Others
  • 4.8 Market Size & Forecast by Device (2020-2035)
    • 4.8.1 Patch Pumps
    • 4.8.2 Tethered Pumps
    • 4.8.3 Smart Insulin Pens
    • 4.8.4 Others
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Integrated Systems
    • 4.9.2 Standalone Systems
    • 4.9.3 Others
  • 4.10 Market Size & Forecast by Mode (2020-2035)
    • 4.10.1 Invasive
    • 4.10.2 Non-invasive
    • 4.10.3 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Component
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Functionality
      • 5.2.1.8 Device
      • 5.2.1.9 Solutions
      • 5.2.1.10 Mode
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Component
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Functionality
      • 5.2.2.8 Device
      • 5.2.2.9 Solutions
      • 5.2.2.10 Mode
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Component
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Functionality
      • 5.2.3.8 Device
      • 5.2.3.9 Solutions
      • 5.2.3.10 Mode
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Component
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Functionality
      • 5.3.1.8 Device
      • 5.3.1.9 Solutions
      • 5.3.1.10 Mode
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Component
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Functionality
      • 5.3.2.8 Device
      • 5.3.2.9 Solutions
      • 5.3.2.10 Mode
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Component
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Functionality
      • 5.3.3.8 Device
      • 5.3.3.9 Solutions
      • 5.3.3.10 Mode
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Component
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Functionality
      • 5.4.1.8 Device
      • 5.4.1.9 Solutions
      • 5.4.1.10 Mode
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Component
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Functionality
      • 5.4.2.8 Device
      • 5.4.2.9 Solutions
      • 5.4.2.10 Mode
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Component
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Functionality
      • 5.4.3.8 Device
      • 5.4.3.9 Solutions
      • 5.4.3.10 Mode
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Component
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Functionality
      • 5.4.4.8 Device
      • 5.4.4.9 Solutions
      • 5.4.4.10 Mode
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Component
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Functionality
      • 5.4.5.8 Device
      • 5.4.5.9 Solutions
      • 5.4.5.10 Mode
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Component
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Functionality
      • 5.4.6.8 Device
      • 5.4.6.9 Solutions
      • 5.4.6.10 Mode
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Component
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Functionality
      • 5.4.7.8 Device
      • 5.4.7.9 Solutions
      • 5.4.7.10 Mode
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Component
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Functionality
      • 5.5.1.8 Device
      • 5.5.1.9 Solutions
      • 5.5.1.10 Mode
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Component
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Functionality
      • 5.5.2.8 Device
      • 5.5.2.9 Solutions
      • 5.5.2.10 Mode
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Component
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Functionality
      • 5.5.3.8 Device
      • 5.5.3.9 Solutions
      • 5.5.3.10 Mode
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Component
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Functionality
      • 5.5.4.8 Device
      • 5.5.4.9 Solutions
      • 5.5.4.10 Mode
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Component
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Functionality
      • 5.5.5.8 Device
      • 5.5.5.9 Solutions
      • 5.5.5.10 Mode
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Component
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Functionality
      • 5.5.6.8 Device
      • 5.5.6.9 Solutions
      • 5.5.6.10 Mode
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Component
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Functionality
      • 5.6.1.8 Device
      • 5.6.1.9 Solutions
      • 5.6.1.10 Mode
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Component
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Functionality
      • 5.6.2.8 Device
      • 5.6.2.9 Solutions
      • 5.6.2.10 Mode
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Component
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Functionality
      • 5.6.3.8 Device
      • 5.6.3.9 Solutions
      • 5.6.3.10 Mode
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Component
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Functionality
      • 5.6.4.8 Device
      • 5.6.4.9 Solutions
      • 5.6.4.10 Mode
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Component
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Functionality
      • 5.6.5.8 Device
      • 5.6.5.9 Solutions
      • 5.6.5.10 Mode

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Medtronic
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Insulet Corporation
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Tandem Diabetes Care
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Dexcom
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Abbott Laboratories
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Roche Diabetes Care
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Ypsomed
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Novo Nordisk
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Sanofi
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Eli Lilly and Company
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Beta Bionics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Bigfoot Biomedical
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Glooko
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Diabeloop
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Senseonics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Biocon
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Cellnovo
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Valeritas
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 DreaMed Diabetes
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 SmartDose Technologies,
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us